image

Report Scope & Overview:

Women’s Health Therapeutics Market size was valued at USD 13.8 billion in 2022 and is expected to reach USD 46.18 billion by 2030 and grow at a CAGR of 16.3% over the forecast period of 2023-2030.

In recent years, a number of factors have contributed to a large increase in the market for medicines for women's health. These include advances in medical research and technology, a growing desire for effective treatments for problems affecting women's health, and greater knowledge and appreciation of women's unique health requirements. The market offers prescription and over-the-counter (OTC) medicines, medical supplies, and remedies. Pharmaceutical and biotechnology companies are primarily responsible for developing and marketing treatments for women's health. They conduct extensive research and clinical testing to bring cutting-edge treatments to market. The market for pharmaceuticals for women's health is active and subject to ongoing regulatory adjustments, clinical studies, and research. Over time, the size of the market and certain therapeutic specialities within women's health may change. Therefore, it is advised to consult the most recent market assessments, industry reports, and expert insights to thoroughly understand the present situation and potential growth areas of the women's health therapeutics market.

Women’s Health Therapeutics Market Revenue Analysis

The regulatory environment for therapies for women's health can be complicated. New drugs or therapies may need to undergo extensive clinical studies and provide proof of their safety and efficacy in order to receive regulatory approval. The process of bringing novel therapies to market may take longer and cost more as a result.

Market Dynamics:
Drivers:

  • The demand for efficient therapies is being driven by the increase in women's health disorders such as polycystic ovary syndrome (PCOS), endometriosis, breast cancer, and osteoporosis.

  • Regulations have been put in place to promote the development of therapies for women's health.

  • Adapting lifestyle and demographic trends.

The need for women's health medicines is expanding as a result of factors such as an ageing population, changing lifestyles, and postponed childbirth. There is a growing emphasis on treatments and therapies that cater to the particular needs of women as they attempt to maintain their health and well-being throughout various life phases.

Restrain:

  • Women's health issues have historically received less attention from researchers and developers than other therapeutic fields.

  • Methods for personalized medicine are lacking.

Treatments can still be customised to meet the unique needs of each woman. The development of personalised medicine strategies may be constrained, and the best possible treatment outcomes may be hampered, by a lack of a thorough understanding of the genetic, hormonal, and lifestyle influences on women's health issues.

Opportunity:

  • Pharmaceutical companies have a huge chance to address these unmet needs by creating breakthrough treatments.

  • Women's health therapies now have more options thanks to the growing use of telemedicine and digital health technologies.      

Challenge:

  • The hormonal changes a woman experiences throughout her life, particularly throughout her menstrual cycle, pregnancy, and menopause, make it difficult to produce effective medications.
  • Like any treatment field, women's health has possible negative consequences and safety issues.

Impact of covid-19:

The pandemic and the ensuing lockdown protocols have had a severe negative impact on mental health. This time's growing tension, fear, and despair have disproportionately affected women. The impact on mental health might necessitate developing and using therapies for problems with female-specific mental health.

The pandemic caused numerous clinical trials and research projects involving treatments for women's health to be postponed or stopped. The discovery of novel medicines and therapies for illnesses affecting women's health may be significantly slowed as a result of this pause in research activity.

Impact of ongoing Recession:

Economic downturns can make healthcare inequities worse and restrict access to treatments, particularly medications for women's health. Due to a loss of employment, a reduction in insurance coverage, or financial hardship, people may struggle to pay for vital prescriptions or access medical facilities.

The pharmaceutical market for women's health may experience market consolidation as a result of a recession. Smaller businesses or startups may find it difficult to raise money or maintain operations, which might result in acquisitions or closures. The variety and accessibility of treatment alternatives may be impacted by this.

Impact of Russia and Ukraine-War:

Women, in particular, are more vulnerable to war's psychological and emotional repercussions. Anxiety and other mental health issues, such as post-traumatic stress disorder (PTSD), could become more common. During and after times of war, it is vital to provide mental health support and the proper treatments for women's mental health disorders.

Conflict-related displacement can lead to overcrowding, poor sanitation, and restricted access to clean water. These elements raise the likelihood that women will experience a range of health problems, such as troubles with their reproductive system and infectious infections. In such circumstances, adequate access to reproductive healthcare services and treatments for women may be jeopardised.

Market Segmentation:

By Type:

  • Pregnancy

  • Oncology

    • Cervical Cancer

    • Ovarian Cancer

    • Uterine Cancer

    • Vaginal & Vulvar Cancer

  • Infection

By Application:

  • Contraceptive drugs

  • dysmenorrhea

  • Antibiotics

  • Antifungals

  • Hormone replacement

  • Acne treatment

  • bone health

Women’s Health Therapeutics Market Segmentation Analysis

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • South Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of the Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

Regional Analysis:

North America, which consists of the United States and Canada, has a substantial market for women's health medications. The region has a robust healthcare infrastructure, state-of-the-art research capabilities, and a high prevalence of illnesses affecting women's health. The market is characterised by a strong emphasis on innovative medicines, regulatory frameworks that encourage drug research, and high healthcare spending.

Women's health therapies have a rapidly expanding market in the Asia-Pacific region. The market is expected to rise as a result of factors like a large population, rising disposable income, rising healthcare costs, and more awareness of women's health issues. As a result of their sizeable populations and growing attention to the development of healthcare infrastructure, nations like China and India have sizable market potential. Women's health therapies have a rapidly expanding market in the Asia-Pacific region. The market is expected to rise as a result of factors like a large population, rising disposable income, rising healthcare costs, and more awareness of women's health issues. As a result of their sizeable populations and growing attention to the development of healthcare infrastructure, nations like China and India have sizable market potential.

Key Players:

The major key players are Pfizer Inc, Novartis AG, Ferring B.V., Apothecus Pharmaceutical Corp, Agile Therapeutics, AstraZeneca, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, Lupin, Eli Lilly and other players listed in the final reports.

Ferring B.V-Company Financial Analysis

Recent Development:

Pfizer Inc: Pfizer Inc. will exhibit at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2–June 6. will share results from its expanding oncology pipeline and product portfolio, including a variety of tumour types. The abstract includes new clinical data for six early pipeline assets and new data from pivotal studies supporting three potential medicines' current regulatory reviews.

Women’s Health Therapeutics Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 13.8 Bn
Market Size by 2030  US$  46.18 Bn
CAGR   CAGR of 16.3% From 2023 to 2030
Base Year 2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Type (Pregnancy, oncology, infection)
• By Application (Contraceptive drugs, dysmenorrhea, Antibiotics, Antifungals, Hormone replacement, Acne treatment, bone health)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Pfizer Inc, Novartis AG, Ferring B.V., Apothecus Pharmaceutical Corp, Agile Therapeutics, AstraZeneca, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, Lupin, Eli Lilly
Key Drivers • The demand for efficient therapies is being driven by the increase in women's health disorders such as polycystic ovary syndrome (PCOS), endometriosis, breast cancer, and osteoporosis.
• Regulations have been put in place to promote the development of therapies for women's health.
Market Opportunities • Pharmaceutical companies have a huge chance to address these unmet needs by creating breakthrough treatments.

 

Frequently Asked Questions

Ans: The Women’s health therapeutics market is to grow at 16.3% Over the Forecast Period 2023-2030.

Ans: The Women’s health therapeutics market is to Hit USD 46.18 Billion by 2030.

Ans: Pfizer Inc, Novartis AG, Ferring B.V., Apothecus Pharmaceutical Corp, Agile Therapeutics, AstraZeneca, Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, Lupin, Eli Lilly.

Ans: The Women’s health therapeutics market size was valued at USD 13.8 Billion in 2022.

Ans: North America was the leading regional segment of contraceptive drugs in 2022.

Table of Contents

1. Introduction 
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of ongoing recession
4.3 Impact of Russia and Ukraine War 

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis 

8. Women’s health therapeutics market Segmentation, By Type
8.1 Pregnancy
8.2 Oncology 
8.2.1 Cervical Cancer
8.2.2 Ovarian Cancer
8.2.3 Uterine Cancer
8.2.4 Vaginal & Vulvar Cancer
8.3 Infection

9. Women’s health therapeutics market Segmentation, By Application
9.1 Contraceptive drugs
9.2 dysmenorrhea
9.3 Antibiotics
9.4 Antifungals
9.5 Hormone replacement 
9.6 Acne treatment
9.7 Bone health

10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Women’s health therapeutics market by Country
10.2.2North America Women’s health therapeutics market by Type
10.2.3 North America Women’s health therapeutics market by Application 
10.2.4 USA
10.2.4.1 USA Women’s health therapeutics market by Type
10.2.4.2 USA Women’s health therapeutics market By Application 
10.2.5 Canada
10.2.5.1 Canada Women’s health therapeutics market by Type
10.2.5.2 Canada Women’s health therapeutics market by Application 
10.2.6 Mexico
10.2.6.1 Mexico Women’s health therapeutics market by Type
10.2.6.2 Mexico Women’s health therapeutics market by Application 
10.3 Europe
10.3.1 Europe Women’s health therapeutics market by Country
10.3.3.2 Europe Women’s health therapeutics market by Type
10.3.3 Europe Women’s health therapeutics market by Application 
10.3.4 Germany
10.3.4.1 Germany Women’s health therapeutics market by Type
11.3.4.2 Germany Women’s health therapeutics market by Application 
10.3.5 UK
10.3.5.1 UK Women’s health therapeutics market by Type
10.3.5.2 UK Women’s health therapeutics market by Application 
10.3.6 France
10.3.6.1 France Women’s health therapeutics market by Type
10.3.6.2 France Women’s health therapeutics market by Application 
10.3.7 Italy
10.3.7.1 Italy Women’s health therapeutics market by Type
10.3.7.2 Italy Women’s health therapeutics market by Application 
10.3.8 Spain
10.3.8.1 Spain Women’s health therapeutics market by Type
10.3.8.2 Spain Women’s health therapeutics market By Application 
10.3.9 The Netherlands
10.3.9.1 Netherlands Women’s health therapeutics market by Type
10.3.9.2 Netherlands Women’s health therapeutics market by Application 
10.3.10 Rest of Europe
10.3.10.1 Rest of Europe Women’s health therapeutics market by Type
10.3.10.2 Rest of Europe Women’s health therapeutics market by Application 
10.4 Asia-Pacific
10.4.1 Asia Pacific Women’s health therapeutics market by Country
10.4.2 Asia Pacific Women’s health therapeutics market by Type
10.4.3 Asia Pacific Women’s health therapeutics market by Application 
10.4.4 Japan
10.4.4.1 Japan Women’s health therapeutics market by Type
10.4.4.2 Japan Women’s health therapeutics market by Application 
10.4.5 South Korea
10.4.5.1 South Korea Women’s health therapeutics market by Type
10.4.5.2 South Korea Women’s health therapeutics market by Application 
10.4.6 China
10.4.6.1 China Women’s health therapeutics market by Type
10.4.6.2 China Women’s health therapeutics market by Application 
10.4.7 India
10.4.7.1 India Women’s health therapeutics market by Type
10.4.7.2 India Women’s health therapeutics market by Application 
10.4.8 Australia
10.4.8.1 Australia Women’s health therapeutics market by Type
10.4.8.2 Australia Women’s health therapeutics market by Application 
10.4.9 Rest of Asia-Pacific
10.4.9.1 APAC Women’s health therapeutics market by Type
10.4.9.2 APAC Women’s health therapeutics market by Application 
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Women’s health therapeutics market by Country
10.5.2 The Middle East & Africa Women’s health therapeutics market by Type
10.5.3 The Middle East & Africa Women’s health therapeutics market by Application 
10.5.4Israel
10.5.4.1 Israel Women’s health therapeutics market by Type
10.5.4.2 Israel Women’s health therapeutics market by Application 
10.5.5 UAE
10.5.5.1 UAE Women’s health therapeutics market by Type
10.5.5.2 UAE Women’s health therapeutics market by Application 
10.5.6 South Africa
10.5.6.1 South Africa Women’s health therapeutics market by Type
10.5.6.2 South Africa Women’s health therapeutics market by Application 
10.5.7 Rest of Middle East & Africa
10.5.7.1 Rest of Middle East & Asia Women’s health therapeutics market by Type
10.5.7.2 Rest of Middle East & Asia Women’s health therapeutics market by Application 
10.6 Latin America
10.6.1 Latin America Women’s health therapeutics market by Country
10.6.2 Latin America Women’s health therapeutics market by Type
10.6.3 Latin America Women’s health therapeutics market by Application 
10.6.4 Brazil
10.6.4.1 Brazil Women’s health therapeutics market by Type
10.6.4.2 Brazil Africa Women’s health therapeutics market by Application 
10.6.5 Argentina
10.6.5.1 Argentina Women’s health therapeutics market by Type
10.6.5.2 Argentina Women’s health therapeutics market by Application 
10.6.6 Rest of Latin America
10.6.6.1 Rest of Latin America Women’s health therapeutics market by Type
10.6.6.2 Rest of Latin America Women’s health therapeutics market by Application 

11. Company profile
11.1 Pfizer Inc
1.1.1 Market Overview
11.1.2 Financials
11.1.3 Product/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Novartis AG
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Product/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 Ferring B.V
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Product/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Apothecus Pharmaceutical Corp
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Product/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Agile Therapeutics
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Product/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 AstraZeneca
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Product/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Merck & Co. Inc
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Product/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Product/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Lupin
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Product/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Eli Lilly
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Product/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View

12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments

13. Used Cases and Best Practices

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone